Aquestive Therapeutics Inc (NASDAQ:AQST) has been given a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and two have given a strong buy rating to the company.
Analysts have set a 12-month consensus price target of $28.67 for the company and are predicting that the company will post ($0.49) EPS for the current quarter, according to Zacks. Zacks has also given Aquestive Therapeutics an industry rank of 87 out of 255 based on the ratings given to related companies.
Several brokerages recently issued reports on AQST. Wedbush began coverage on Aquestive Therapeutics in a research report on Wednesday, September 12th. They issued an “outperform” rating and a $33.00 price target on the stock. BMO Capital Markets began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They issued an “outperform” rating on the stock. Royal Bank of Canada began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, JMP Securities began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They issued an “outperform” rating and a $29.00 price target on the stock.
In related news, Director Douglas K. Bratton purchased 165,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $2,475,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of AQST stock opened at $14.90 on Friday. Aquestive Therapeutics has a 52-week low of $13.61 and a 52-week high of $20.70. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of -1.16.
Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, September 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($1.66). The company had revenue of $13.93 million during the quarter. On average, analysts anticipate that Aquestive Therapeutics will post -0.93 earnings per share for the current year.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Recommended Story: What Are Treasury Bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.